MedTrace Logo

Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis

NCT00333385 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2006-06-05

No results posted yet for this study

Summary

The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.

Conditions

Interventions

DRUG

ceftazidime

Sponsors & Collaborators

  • Vaincre la Mucoviscidose

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Baxter Healthcare Corporation

    collaborator INDUSTRY

  • Roche Pharma AG

    collaborator INDUSTRY

  • Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche

    lead OTHER

Principal Investigators

  • Dominique Hubert, MD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Completion
2004-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00333385 on ClinicalTrials.gov